Eli Lilly retatrutide obesity-drug approval path

Mapped to your portfolio

Overview

Description Eli Lilly is advancing retatrutide toward an obesity-drug regulatory filing after Phase 3 weight-loss results. Overview Eli Lilly reported Phase 3 results for retatrutide in patients with obesity. Patients using a 12 mg dose lost an average of 49.6 pounds, or 20.8%, over 80 weeks in one reported result. A subsequent…

Possible scenarios

74%Eli Lilly retatrutide U.S. regulatory-path setback by March 31, 2027-0.1%
24%Retatrutide advances into substantive U.S. FDA obesity review+0.1%

For information only. Not investment advice.

Stories in this saga

1 story, 3 sources

Sep 30, 2026
Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial
- Eli Lilly Retatrutide Drops 59.5% of Participants Below Obesity BMI21 days ago
- Eli Lilly Drug Combo Achieves 23.3% Weight Loss in Diabetes Study21 days ago

Mapped to your portfolio

Overview

Possible scenarios

Keeping an eye on this saga?

Stories in this saga

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Portfolio

Possible scenarios

Mapped to your portfolio